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ABSTRACT 
Objectives: Preeclampsia is one of the most feared complications of pregnancy, which can 
progress rapidly to serious complications such as death of both mother and fetus. To present, the 
leading cause of preeclampsia is still debated. The purpose of this article was to explore the 
  
clinical significance of S100B protein, a kind of Ca2+ -sensor protein, in the early-onset severe 
preeclampsia.  
Material and methods: Nine pregnant women with early-onset severe preeclampsia (the study 
group) and 13 healthy pregnant women (the control group) were included in this study. The level 
of S100B in the amniotic fluid, maternal blood, and umbilical cord blood were detected by 
enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance imaging (SPRi) 
methods. Diagnostic values of S100B for early-onset severe preeclampsia were assessed by 
Receiver Operating Characteristic (ROC) curve analysis.  
Results: The levels of S100B in maternal blood and amniotic fluid in the study group were 
higher than those in the control group (p < 0.05). ROC curve analysis showed that S100B 
detected by SPRi method (SPRi-S100B) showed a cut-off level of 181 ng/mL with sensitivity of 
100%, a specificity of 84.6%, and a Youden index of 0.846 in the maternal blood, which had 
better clinical significance and diagnostic value (at than that detected by ELISA (ELISA-S100B).    
Conclusions: The levels of S100B detected by SPRi in maternal blood can indicate early-onset 
severe preeclampsia and perinatal brain injury. 
Key words: S100B; early-onset severe preeclampsia; enzyme-linked immunosorbent assay; 
surface plasmon resonance imaging  
 
INTRODUCTION 
Preeclampsia is a severe condition with high blood pressure and increased protein in the 
urine in pregnant women. It commonly occurs after gestational week 20 and can be divided into 
early-onset (< 34 weeks) and late-onset (> 34 weeks) preeclampsia. It is believed that early-onset 
and late-onset preeclampsia have different aetiologies and pathogenesis, although both can cause 
high morbidity and mortality for pregnant women and fetuses [1, 2]. Prompt recognition and 
diagnosis of preeclampsia and perinatal brain injury (PBI) are essential to save lives and improve 
outcomes [3]. However, most clinical studies have focused on late-onset preeclampsia, and 
relatively few studies investigated early-onset preeclampsia. 
Researchers have searched for various markers of brain injury to diagnose preeclampsia 
and PBI early, as preeclampsia can cause PBI in the fetus. Perinatal brain injury (PBI) is the main 
cause of perinatal death and long-term disability. It is reported that 8% of full-term infants suffer 
from cerebral palsy due to asphyxia at birth, and 40% of preterm infants die of perinatal death 
  
due to neurological defects [4]. Pierrat et al. [5], (2005) found that prenatal-perinatal asphyxia 
accounts for 10% and postpartum asphyxia accounts for 2% in newborn encephalopathy. At 
present, scholars lack a unified understanding of the diagnosis of this condition. Current 
understanding of PBI by obstetricians is that preventive measures must be taken in a timely 
manner; however, this remains controversial. Therefore, measures must be taken to diagnose PBI 
in a timely and accurate manner.  
Several studies have reported that the S100B protein expression is elevated in pregnant 
women with preeclampsia, indicating the involvement of S100B protein in preeclampsia [6]. The 
S100B protein synthesized and secreted by brain neuroglia and Schwann cells is a member of the 
S100 protein family (calcium-regulation protein) [7]. It acts as both an intracellular regulator and 
a secreted signaling molecule and plays important roles in many cellular processes such as cell 
proliferation, differentiation, migration, and apoptosis [8]. Alterations in the level of expression 
of S100B can lead to four different categories of diseases including the heart disease, central 
nervous system disease, inflammatory disorders and cancer [9]. It was found that the effects and 
physiological functions of S100B are concentration dependent. A low concentration (nanomolar 
level) of S100B can nourish and support the neuroglia and neurons, which facilitates nerve 
growth and injury repair. A high concentration (micromolar level) of S100B can have toxic 
effects on nerves to induce neuron degeneration apoptosis and death [10]. S100B is sensitive 
enough to detect and evaluate different types of intracranial trauma, such as traumatic 
subarachnoid hemorrhages and epidural hematomas, depending on the receptor for advanced 
glycation end-products (RAGE) which is up-regulated by S100B levels and may lead to pro-
inflammatory gene activation [11]. Some researchers have described S100B as “the C-reactive 
protein (CRP) of the brain.” [12] and suggested its use in monitoring fetal distress and other high-
risk fetuses [13]. In 2012, Cai et al. [14], reported that the S100B expression in women with 
early-onset preeclampsia was significantly higher than that in the control group and in late-onset 
preeclampsia group, indicating that S100B may be a risk factor in early-onset preeclampsia. 
Serum S100B levels may also be suitable markers of severe preeclampsia given the severity of 
hypoperfusion both in the placenta and brain [15]. In another previous study, S100B levels were 
found to be much higher in women with preeclampsia than that in control subjects, and high 
S100B is significantly associated with visual impairment in the preeclampsia group [6] S100B 
protein may help obstetrician screen for PBI, monitor the progression of the disease, identify the 
  
timing of the injury, and predict the time of birth [16]. The level of S100B may be an ideal 
indicator for the diagnosis in preeclampsia and PBI, however, it is difficult to detect S100B at the 
mRNA level in clinical laboratories. 
In our study, we examined the S100B expression levels in the maternal blood, amniotic 
fluid, and umbilical cord blood in pregnant women with preeclampsia using ELISA and SPRi and 
evaluated specificity and sensitivity of two methods to detect S100B for identification of early-
onset severe preeclampsia and PBI. 
 
MATERIALS AND METHODS 
Study design and ethical approval 
This retrospective study protocol was approved by the Ethics Committee of the Maternal 
and Child Health Hospital of Hunan Province (No. 2013-P2-006-01) and complied with the 
Declaration of Helsinki. Informed consents were obtained from all participants. 
 
Patients 
Between January 2017 and December 2018, nine pregnant women with early-onset severe 
preeclampsia, showing fetal distress and causing hypoxic-ischemic encephalopathy (HIE) after 
delivery, and 13 pregnant women without early-onset severe preeclampsia and having prenatal 
diagnosis when they were 32–34 weeks pregnant at the Maternal and Child Health Hospital of 
Hunan Province, were assessed for eligibility based on inclusion and exclusion criteria. Their 
nationality, age, parity, fetal number, weeks pregnant, inflammation status, tumor status, and 
family history of hypertension were recorded. 
Inclusion criteria:  1. they were diagnosed fetal distress by non-stress test and ultrasound 
and caused hypoxic-ischemic encephalopathy after delivery; 2. Han nationality; 3. 35 years old; 
4. Primiparous; 5. Singleton pregnancies; 6; 32–34 weeks pregnant; 7. No inflammation; 8. No 
tumors, and 9. No family history of hypertension. Pregnant women included in the control group:  
1. Perinatal and they delivered baby in full-term smoothly; 2. Han people; 3. 35 years old; 4. 
Primiparity; 5. Singleton pregnancy; 6. 32–34 weeks pregnant; 7. No inflammation; 8. No tumors  




In the control group, we obtained 3 mL of blood from the pregnant women’s antecubital 
veins at 8:00 a.m. and 5 mL amniotic fluid from the amniotic sac of the uterus at 4:00 p.m. In the 
study group, in addition to the peripheral veins and amniotic fluid, we also collected 3 mL of 
blood from the umbilical vein in the operating room in cases of fetuses with diagnosed fetal 
distress in utero by non-stress test (NST) and ultrasound. All samples were centrifuged at 3,500 
rpm at 4°C for 15 min. Supernatants were deposited at −80°C. The S100B protein expression was 
detected using enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance 
imaging (SPRi) in the hospital laboratory according to the instruction manual [17, 18]. 
 
Statistical analysis 
The data were analyzed with Statistical Product and Service Solutions (SPSS) version 
25.0 software (IBM, Chicago, IL, USA). S100B concentrations were presented as the mean ± 
standard deviation (SD), and compared by Wilcoxcon rank sum test. The correlation of S100B 
levels among maternal blood, cord blood, and amniotic fluid in the study and control groups were 
evaluated using Spearman’s correlation test. Receiver operating characteristic (ROC) curve 
analysis was assessed for early-onset severe preeclampsia and PBI diagnostic values of the 




Characteristics of study participants 
The baseline characteristics of maternal and fetus status in the control and study groups 
were listed in Table 1. It was suggested that there were no significances in pregnant week and 
body mass index (BMI) for pregnant women in both groups. Blood pressure was 160-190/100-
120 mmHg in the study group and lower than 140/90 mmHg in the control group. 2+ to 4+ 
proteinuria was found in the study group, while — proteinuria was observed in the control group. 
Results of fetal status suggested that non-stress test was abnormal for the study group and normal 
for the control group. Ultrasound score was 4–6 for the study group and 8 for the control group. 




Concentrations of S100B protein in the study and control groups 
As shown in Table 2, there were no statistical differences in the concentration of S100B 
protein in the amniotic fluid tested by ELISA between the study group and the control group (p > 
0.05). Following SPRi measurement, a significant difference in the concentration of S100B 
protein in the amniotic fluid was found between two groups (p < 0.05). Furthermore, there was a 
significant difference in the concentration of S100B protein in maternal blood between the study 
group and the control group tested by ELISA and SPRi methods (both p < 0.05). 
 
Correlation of concentrations of S100B between maternal blood and amniotic fluid in the 
control and study groups 
As shown in Table 3, for the study group, the concentration of ELISA-S100B protein in 
maternal blood was positively correlated with the concentration of SPRi-S100B protein in 
maternal blood (0.883, p < 0.05). The concentration of ELISA-S100B in amniotic fluid was 
positively correlated with the concentration of SPRi-S100B in amniotic fluid (0.720, p < 0.05). 
However, there were no positive correlations between ELISA-S100B protein in the maternal 
blood and ELISA-S100B and or SPRi-S100B in amniotic fluid, between SPRi-S100B in maternal 
blood and ELISA-S100B and or SPRi-S100B in amniotic fluid (p > 0.05).  
 
Correlation of ELISA-S100B and SPRi-S100B concentrations in study group 
For the study group, Table 4 showed that there was a positive correlation between ELISA-
S100B expression level and SPRi-S100B expression level in maternal blood (0.850, p < 0.05) 
and ELISA-S100B in umbilical cord blood (0.741, p < 0.05)  between SPRi-S100B in maternal 
blood and  ELISA-S100B in umbilical cord blood (0.706, p < 0.05), and or SPRi-S100B in 
umbilical cord blood (0.620, p < 0.05) and in  amniotic fluid (0.579, p  < 0.05).  By contrast, 
there were no positive correlations between the ELISA-S100B in the maternal blood and ELISA-
S100B and or SPRi-S100B in the amniotic fluid and SPRi-S100B in the umbilical cord blood 
(p > 0.05). There were no positive correlations for ELISA-S100B in umbilical cord blood and 
ELISA-S100B and SPRi-S100B in the amniotic fluid, and the SPRi-S100B in the umbilical cord 
blood (p > 0.05). The ELISA-S100B expression level in amniotic fluid was not positively 
correlated with the SPRi-S100B in maternal blood, in umbilical cord blood and in amniotic fluid 
  
(p > 0.05). There were no statistical differences in SPRi-S100B between the amniotic fluid and 
the umbilical cord blood (p > 0.05). 
 
ROC analysis for ELISA-S100B and SPRi-S100B 
Table 5 and Figure 1 showed ELISA-S100B and SPRi-S100B in maternal blood and in 
amniotic fluid. ROC analysis proved that the area under ROC curve (AUC) of SPRi-S100B in 
maternal blood was 0.959 (p < 0.001), which was greater than that of ELISA-S100B in maternal 
blood of 0.846 (p = 0.07). The AUC of SPRi-S100B in amniotic fluid was 0.858 (p = 0.002), 
which was greater than that of ELISA-S100B in amniotic fluid of 0.709 (p = 0.102). There were 
no statistical differences in the AUC for ELISA-S100B in amniotic fluid (p > 0.05). Additionally, 
the sensitivity and specificity of ELISA and SPRi were provided in Table 6. The cut-off level for 
detecting ELISA-S100B and SPRi-S100B in maternal blood was 178 ng/mL and 181 ng/mL, the 
sensitivity was 66.7% and 100%, and the specificity was 44.4% and 84.6%, respectively. The 
cut-off level for detecting ELISA-S100B and SPRi-S100B in amniotic fluid was 126 ng/mL and 
99 ng/mL, the sensitivity was 0% and 100%, and the specificity was 0% and 69.2%, respectively.  
Above findings indicated that SPRi-S100B is superior to the ELISA-S100B for the diagnosis of 
early-onset severe preeclampsia in pregnant women.  
 
DISCUSSION 
In pregnant women with early-onset and severe preeclampsia, arteriolar convulsions can 
cause fetal distress through poor placental perfusion, which can lead to PBI and neonatal hypoxic 
ischemic encephalopathy. Despite these potential issues, screening high-risk fetuses for brain 
injury early and accurately remains challenging [2]. In this study, the concentrations of S100B 
protein in samples of pregnant women with and without preeclampsia were detected by ELISA 
and SPRi methods, and ithe feasibility, safety and accuracy of ELISA and SPRi were evaluated, 
providing the evidence that SPRi-S100B protein level can accurately and reliably provide clinical 
benefits to identify early-onset severe preeclampsia. 
S100B is a calcium-binding protein concentrated in nervous glial cells, which is essential 
to oligodendrocyte (OL) differentiation and maturation. Elevated S100B is suggested to disrupt 
astrocyte proliferation and inflammation while destroy neuronal and synaptic integrity, reduce the 
morphological maturation of differentiated OL [11]. The high S100B levels in biological fluids 
  
are thus considered biomarkers of pathological conditions in many brain disorders [12]. Serum 
S100B levels can be used not only as a biomarker for hypoxic-ischemic encephalopathy, but also 
as a useful marker of perinatal acute brain injury, especially for fetal distress [2, 10, 21]. Also, it 
has been used to monitor brain damage and evaluate neuroprotective effects in high-risk 
newborns [22, 23]. S100B concentration was also found to be associated with umbilical artery 
pH, amplitude integral electroencephalogram (EEG), hypoxic ischemic encephalopathy (HIE) 
stage and death/sequelae up to age 6 [24]. S100B was positively correlated with the severity of 
the disease and the risk of neurodevelopmental sequelae and death [25]. The elevation of plasma 
S100B in patients with preeclampsia may be secondary to cerebral vascular injury, suggesting 
that the brain is involved in the occurrence of preeclampsia [26]. In addition, for preeclampsia, 
reactive oxygen species (ROS) are produced by oxidative stress, which can increase S100B levels 
in amnion [27]. In a previous study, the severe preeclampsia showed higher S100B levels than 
the mild preeclampsia or normotensive [28]. Levels of S100B remained higher in women who 
had experienced preeclampsia in one year postpartum than those with previous normal 
pregnancies [30]. S100B should be a potential biomarker of the central nervous system (CNS), as 
well as in perinatal development and damage [31]. S100B is also applied to monitor the effect of 
maternal prenatal treatment, such as the administration of NO and glucocorticoids [32]. In this 
study, compared to the control, increased expression levels of S100B protein in maternal blood 
and amniotic fluid of pregnant women with early-onset severe preeclampsia were found. 
Previous studies reported that ELISA can be used to detect changes in S100B concentration in 
serum and cerebrospinal fluid (CSF) with high sensitivity and specificity, and it should be a 
simple diagnosis tool for preeclampsia [32, 33]. SPRi is a label-free, real-time method to monitor 
and diagnose fetal diseases [34, 35]. This study indicated that there are significant differences in 
concentrations of S100B in maternal blood between the two groups assayed by ELISA and SPRi. 
Previous studies showed that high S100B protein levels indicate development of PBI [24]. 
Additionally, the Youden index of SPRi-S100B in pregnant women's blood and amniotic fluid 
were higher than the control, indicating a greater diagnostic value. Based on these results, it was 
believed that the SPRi-S100B used as an indicator of early-onset severe preeclampsia is better 
than that of ELISA-S100B. Overall, our experiments provide real-time, non-invasive, and relative 
quantitative estimates of early-onset severe preeclampsia, as well as preliminary evidence for 




This is a study with fewer cases from a single center, so results may not accurately 
represent populations in different geographic areas. Future studies will require more patients and 
careful matching of key clinical indicators to ultimately quantify the potential clinical value of 
PBI and early onset of severe preeclampsia using the SPRi-S100B. 
 
CONCLUSIONS 
Increased levels of S100B are found in maternal blood and amniotic fluid of pregnant 
women with early-onset severe preeclampsia compared to healthy pregnant women. There was a 
positive correlation in S100B concentration between maternal blood and amniotic fluid. SPRi-
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Figure 1. Receiver Operating Characteristic (ROC) curve of S100B protein in blood and 
amniotic fluid of pregnant women with preeclampsia detected by ELISA and SPRi; A. ROC of 
ELISA-S100B in maternal blood; B. ROC of ELISA-S100B in amniotic fluid; C. ROC of SPRi-
S100B in maternal blood; D. ROC of SPRi-S100B in amniotic fluid 
 
Table 1. Baseline characteristics of maternal and fetus status in both study and control groups 
Items Study group Control group 
Maternal status   
  
Pregnant week 32–34 32–34 
BMI 18–25 18–25 
Blood pressure 
[mmHg] 
160–190/100–120 < 140/90 
Proteinuria ++ to ++++ – 
Fetal status   
Non-stress test Abnormal Normal 
Ultrasound scores 4–6 8 
Weight Fetal growth restriction Normal 
BMI — body mass index 
 
 
Table 2. Comparison of the ELISA-S100B and SPRi-S100B in study and control groups  
Variables Control group (n = 13) Study group (n = 9) Z p 
Maternal blood (ELISA-S100B) 111.63 ± 42.64 198.91 ± 51.02 2.709 0.007 
Maternal blood (SPRi-S100B) 115.18 ± 51.02 209.01 ± 27.54 3.976 0.000 
Amniotic fluid (ELISA-S100B) 168.49 ± 37.33 144.93 ± 42.74 1.637 0.102 
Amniotic fluid (SPRi-S100B) 82.88 ± 45.12 142.88 ± 22.93 3.103 0.002 
 
Table 3. Correlations of S100B protein concentrations in the control group between maternal 
blood and amniotic fluid  










1.000    
Amniotic fluid (ELISA-
S100B) 




0.883** 0.016 1.000  
Amniotic fluid (SPRi-
S100B) 
0.055 0.720** 0.121 1.000 
** indicated p <0.05 
 


























1.000      
Umbilical cord blood 
(ELISA-S100B) 
0.741* 1.000     
Amniotic fluid (ELISA-
S100B) 
0.213 0.650 1.000    
Maternal blood (SPRi-
S100B) 
0.850** 0.706* 0.176 1.000   
Umbilical cord blood (SPRi-
S100B)  
0.562 0.517 0.233 0.620* 1.000  
Amniotic fluid (SPRi-S100B)  0.443 0.333 0.533 0.579* 0.313 1.000 
*indicated p < 0.05; **indicated p < 0.01.  
 
Table 5. Receiver Operating Characteristic analysis of the S100B protein concentration 
 AUC p 95% CI 
Maternal blood (ELISA-S100B) 0.846 0.007 0.672–1.000 
Maternal blood (SPRi-S100B) 0.959 0.000 0.888–1.000 
Amniotic fluid (ELISA-S100B) 0.709 0.102 0.463–0.956 
Amniotic fluid (SPRi-S100B) 0.858 0.002 0.705–1.000 
AUC — the area under ROC curve; CI — confidence interval 
  
 
Table 6. Clinical significance of S100B protein detected by SPRi and ELISA in maternal blood 
and amniotic fluid  
 Sensitivity Specificity Youden Index 
Maternal blood (ELISA-
S100B) 
0.667 1.000 0.667 
Maternal blood (SPRi-
S100B) 
1.000 0.846 0.846 
Amniotic fluid (ELISA-
S100B) 
0.444 0.000 −0.556 
Amniotic fluid (SPRi-
S100B) 
1.000 0.692 0.692 
 
 
